Literature DB >> 23180982

Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy.

Romain Coriat1, Pascaline Boudou-Rouquette, Jean-Philippe Durand, Priscille Forgeot d'Arc, Idalie Martin, Olivier Mir, Stanislas Ropert, Jérôme Alexandre, François Goldwasser.   

Abstract

PURPOSE: Ambulatory chemotherapy is patient friendly but may result in toxicity-induced unscheduled hospitalizations (TIUHs). This emerging issue may increase health care costs. We studied the cost effectiveness of a hospital-home monitoring program based on systematic iterative telephone calls after chemotherapy. PATIENTS AND METHODS: We retrospectively evaluated the rates of chemotherapy-induced unscheduled hospitalizations in patients who were treated in August 2008. Patients were contacted by telephone 1 day before chemotherapy and on the second and eighth days after undergoing chemotherapy. Costs associated with TIUHs were calculated and compared with those of a cohort concomitantly treated using the standard follow-up procedure.
RESULTS: A total of 259 patients entered the hospital-home monitoring program. They were compared with 86 patients who had similar characteristics but underwent the standard treatment and follow-up procedure. Inclusion in the hospital-home monitoring program resulted in patients experiencing TIUHs approximately half as frequently as patients in the other group (2.4% v 4.9%; P < .01). Patients in the program experienced TIUHs for a median length of stay of 4 days, representing a nonsignificant reduction in duration of hospitalization (P not significant). Consequently, through a two-fold reduction in TIUH annual incidence, this program represents a reduction in unscheduled hospitalizations per year of 383 days, decreasing hospital costs by €201.468 ($292,468) per year.
CONCLUSION: The hospital-home monitoring program is a cost-effective strategy for offering ambulatory chemotherapy treatment to patients with cancer. This program has become our standard procedure for ambulatory chemotherapy in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180982      PMCID: PMC3396813          DOI: 10.1200/JOP.2011.000447

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  16 in total

1.  Practical utility of case-management telephone intervention in heart failure?

Authors:  Gregory M Peterson
Journal:  Arch Intern Med       Date:  2002-10-14

2.  Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.

Authors:  J Alexandre; P Bleuzen; J Bonneterre; W Sutherland; J L Misset; J Guastalla; P Viens; S Faivre; A Chahine; M Spielman; A Bensmaïne; M Marty; M Mahjoubi; E Cvitkovic
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  How healthcare wins with consumers who want more.

Authors:  Quint Studer
Journal:  Front Health Serv Manage       Date:  2003

4.  Treatment satisfaction as an outcome measure in cancer clinical treatment trials.

Authors:  Anne Brédart; Andrew Bottomley
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2002-12       Impact factor: 2.217

5.  Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.

Authors:  Angela Ihbe-Heffinger; Bernadette J Paessens; Christoph von Schilling; Margarita Shlaen; Nina Gottschalk; Karin Berger; Rudolf Bernard; Marion Kiechle; Christian Peschel; Volker R Jacobs
Journal:  Onkologie       Date:  2011-04-26

6.  The impact of follow-up telephone calls to patients after hospitalization.

Authors:  V Dudas; T Bookwalter; K M Kerr; S Z Pantilat
Journal:  Am J Med       Date:  2001-12-21       Impact factor: 4.965

7.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

8.  An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

Authors:  Olivier Mir; Romain Coriat; Laure Cabanes; Stanislas Ropert; Bertrand Billemont; Jérôme Alexandre; Jean-Philippe Durand; Jean-Marc Treluyer; Bertrand Knebelmann; François Goldwasser
Journal:  Oncologist       Date:  2011-08-01

9.  Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.

Authors:  Charles L Bennett; Elizabeth A Calhoun
Journal:  Oncologist       Date:  2007-04

Review 10.  Economic burden of haematological adverse effects in cancer patients: a systematic review.

Authors:  S Y Liou; J M Stephens; K T Carpiuc; W Feng; M F Botteman; J W Hay
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more
  3 in total

1.  Cost effectiveness of integrated medicine.

Authors:  John A Fallon
Journal:  J Oncol Pract       Date:  2012-06-05       Impact factor: 3.840

2.  The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward.

Authors:  C Jara; F Ayala; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2017-01-12       Impact factor: 3.405

3.  Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer.

Authors:  Monika K Krzyzanowska; Cassandra MacKay; Heekyung Han; Maria Eberg; Sonal Gandhi; Nicole B Laferriere; Melanie Powis; Doris Howell; Clare L Atzema; Kelvin K W Chan; Vishal Kukreti; Sandra Mitchell; Marla Nayer; Mark Pasetka; Dafna Knittel-Keren; Erin Redwood
Journal:  Pilot Feasibility Stud       Date:  2019-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.